Washington, DC 20549












Date of Report (Date of earliest event reported): June 26, 2020




Onconova Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)




Delaware   001-36020   22-3627252
(State or Other Jurisdiction
of Incorporation or Organization)
File Number)
  (I.R.S. Employer
Identification No.)


375 Pheasant Run

Newtown, PA 18940

(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive



Not Applicable

(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.01 per share   ONTX   The Nasdaq Stock Market LLC
Common Stock Warrants   ONTXW   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  ¨







Item 5.07. Submission of Matters to a Vote of Security Holders.


Onconova Therapeutics, Inc. (the “Company”) previously disclosed the vote results for Proposals 1, 3, 4, 5 and 6, each as set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 23, 2020 (the Proxy Statement”) for the Company’s 2020 Annual Meeting of Stockholders held on May 27, 2020 (the “Annual Meeting”) under Item 5.07 in the Company’s Current Report on Form 8-K filed with the SEC on June 2, 2020.


The Company also previously disclosed that it adjourned the Annual Meeting to June 26, 2020 (the “Reconvened Annual Meeting”) to give the Company’s stockholders additional time to consider and vote on Proposal 2 regarding a reverse stock split as set forth in the 2020 Proxy Statement. The Company subsequently disclosed that, based on feedback from the Company’s stockholders, the Company intended to withdraw Proposal 2 from consideration by the Company’s stockholders at the Reconvened Annual Meeting and added Proposals 7 and 8 as matters to be voted on at the Reconvened Annual Meeting and distributed relevant additional proxy materials to the Company’s stockholders.


On June 26, 2020, the Company held the Reconvened Annual Meeting. At the Reconvened Annual Meeting, the Company withdrew Proposal 2 and the Company’s stockholders voted on the following proposals:


Proposal 7. To consider and vote upon Amendment 2020-1 to the 2018 Omnibus Incentive Compensation Plan, as amended and restated. The proposal was not approved by a vote of the stockholders as follows:


For   Against   Abstain   Broker Non-Votes  
12,129,142   13,499,081   3,059,252   None  


Proposal 8. To consider and vote upon a proposal to adjourn the Reconvened Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Reconvened Annual Meeting to approve Proposal 7. The proposal was not approved by a vote of the stockholders as follows:


For   Against   Abstain   Broker Non-Votes  
12,476,244   14,092,722   2,118,509   None  







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: July 2, 2020   Onconova Therapeutics, Inc.
    By: /s/ MARK GUERIN
      Name: Mark Guerin
      Title: Chief Financial Officer